Vaccine under development provides the “most comprehensive coverage” to date and alleviates antimicrobial concerns, new study finds
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.
Better access to antibiotics and improved nutrition account for part of the decline. But scientists say it’s mostly due to vaccines introduced in the early 2000s that target up to 23 of the most deadly forms of the bacterium that causes pneumonia, Streptococcus pneumoniae.
Now, a new vaccine under development could deal another blow to the disease, lowering the number of deaths even further by targeting dozens of additional strains of S. pneumoniae, and anticipating future versions of the bacteria responsible for the disease.
The vaccine provoked an immune response to 72 forms of S. pneumoniae — including the 23 mentioned above — in lab tests on animals, according to new research published today (Oct. 20, 2017) in the journal Science Advances. The study represents the “most comprehensive” coverage of pneumococcal disease to date, researchers say.
“We’ve made tremendous progress fighting the spread of pneumonia, especially among children. But if we’re ever going to rid ourselves of the disease, we need to create smarter and more cost-effective vaccines,” says Blaine Pfeifer, PhD, associate professor of chemical and biological engineering at the University at Buffalo’s School of Engineering and Applied Sciences, and the study’s co-lead author.
The limitation of existing vaccines
Each strain of S. pneumoniae contains unique polysaccharides. Vaccines such as Prevnar 13 and Synflorix connect these sugars — by the sharing of an electron — to a protein called CRM197. The process, known as a covalent bond, creates a potent vaccine that prompts the body to find and destroy bacteria before it colonizes the body.
While effective, creating covalent bonds for each strain of S. pneumoniae is time-consuming and expensive. Plus, this type of immunization, known as a conjugate vaccine, prompts the body to eliminate each of the targeted bacteria types — regardless of whether the bacteria is idyll or attacking the body.
Another vaccine, Pneumovax 23, contains sugars of 23 of the most common types S. pneumoniae. However, the immune response it provokes is not as strong as Prevnar because the sugars are not covalently linked.
“Traditional vaccines completely remove bacteria from the body. But we now know that bacteria — and in a larger sense, the microbiome — are beneficial to maintaining good health, says Charles H. Jones, the study’s other co-lead author.
“What’s really exciting is that we now have the ability — with the vaccine we’re developing — to watch over bacteria and attack it only if it breaks away from the colony to cause an illness. That’s important because if we leave the harmless bacteria in place, it prevents other harmful bacteria from filling that space.”
Jones, who earned a PhD while working in Pfeifer’s lab, has formed a company, Abcombi Biosciences, to bring the vaccine and other pharmaceutical products to market. The company is part of the START-UP NY economic development program, was a finalist for the 43North business plan competition in 2016 and has received seed funding and other support from UB.
Co-authors of the study from UB’s engineering school include Guojian Zhang, Roozbeh Nayerhoda, Marie Beitelshees (also of Abcombi), Andrew Hill (also of Abcombi) and Yi Li; Bruce A. Davison and Paul Knight III, both faculty members from the Jacobs School of Medicine and Biomedical Sciences at UB; and Pooya Rostami of New York University’s Langone Medical Center.
How the new vaccine works
Varieties of S. pneumoniae not covered by current immunizations are responsible for a small portion — for example, 7 to 10 percent among U.S. children, according to the Centers for Disease Control and Prevention — of pneumonia, meningitis and other cases of pneumococcal disease.
But officials worry that will change, as these less common forms — and, potentially, yet-to-be discovered antimicrobial resistant strains — replace the 23 more common types targeted by current immunizations.
The new vaccine provokes a strong immune response (comparable to Prevnar) and is engineered in a way that makes it easy to add sugars (like Pneumovax) for a broad immune response.
Key to the technology is a liposome — a tiny liquid-filled bubble made of fat — that acts as a storage tank for the sugars. Because the sugars are not covalently bonded, it’s possible that the liposome could host all of the sugars that identify individual strains of S. pneumoniae.
The research team added proteins at the surface of the liposome (also non-covalently) which, together with the sugars, provoke strong immunotherapy. According to tests performed on mice and rabbits, the new vaccine stimulated an immune response to 72 of the more than 90 known strains of S. pneumoniae. In many cases, it outperformed Prevnar and Pneumovax.
“The advantage of our approach is that we don’t have to apply the more complex covalent chemistry that is required for Prevnar,” Pfeifer says. “As a result, we can extend beyond the 13 types of sugars, potentially providing universal coverage against bacteria that causes pneumonia, meningitis, sepsis and other types of pneumococcal disease.
“It holds the promise of saving hundreds of thousands of lives each year.”
Learn more: The end of pneumonia? New vaccine offers hope.
The Latest on: Pneumonia
- Pneumonia cases linked to vaping are still rising. And federal officials don’t know what’s causing themon September 6, 2019 at 11:19 am
The Centers for Disease Control and Prevention reported a rising number of cases of mysterious pneumonias linked to vaping on Friday. Now, the agency reports 450 people from 33 states and one U.S.
- Community Acquired Pneumonia Market to grow with 8.1% CAGR during the forecast period of 2019-2025on September 6, 2019 at 5:57 am
Sep 06, 2019 (The Expresswire) -- The global Community Acquired Pneumonia Market is estimated to generate $4.9 billion as of 2018 with demand-pull inflation, which will lead the market to grow with ...
- Sarri returns to take Juventus training as pneumonia recovery continueson September 4, 2019 at 1:18 pm
Maurizio Sarri has returned to the training field with Juventus as he continues his recovery following a bout of pneumonia. The 60-year-old was diagnosed with pneumonia in mid-August and was ...
- Global Pneumonia Therapeutics Market is Expected to Reach USD 26.37 Billion by 2025 : Fior Marketson September 4, 2019 at 4:45 am
New Jersey, NJ, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Growing geriatric population around the world, growing incidence of pneumococcal disease and increasing levels of pollution are driving the global ...
- Can You Have Pneumonia Without a Fever?on September 3, 2019 at 4:51 pm
Pneumonia is a respiratory infection where the tiny air sacs in your lungs become inflamed and filled with fluid. It can range in severity from mild to life-threatening. Although fever is a common ...
- Doctors Without Borders criticizes the Gavi coalition over access to pneumonia vaccineson September 3, 2019 at 12:23 pm
A flap has broken out between Gavi, the Vaccine Alliance, and Doctors Without Borders over funding commitments for pneumonia vaccines at accessible prices for developing countries. At issue is the ...
- Pneumonia uses hydrogen peroxide to weaken the immune systemon September 2, 2019 at 11:17 pm
Pneumonia is a lung infection, filling up the alveoli with pus and fluid. At present, it’s the leading cause of death among children. The lung infection accounts for 15 percent of all deaths in ...
- Bacteria in pneumonia attack using bleaching agenton September 2, 2019 at 4:16 pm
Research shows that bacteria use hydrogen peroxide to weaken the immune system and cause pneumonia. Hydrogen peroxide is also known as a bleaching agent that is used to whiten teeth or hair, as a ...
- N.J. hospitals treated 58k flu, pneumonia cases last year. Vaccines could have prevented most, study says.on September 1, 2019 at 6:01 am
Back-to-school season sparks some tense conversations about vaccinations, and pediatrician Harry Banschick said he’s preparing to deal with the handful of parents who refuse to comply. The doctor said ...
- How Can You Get Chemical Pneumonia From Vaping? Pulmonologists Explainon August 29, 2019 at 12:00 pm
There's no way around it: The dangers of vaping are showing up everywhere—and now, the city of Milwaukee is urging its residents to immediately stop any use of vaping or e-cigarette devices. On ...
via Google News and Bing News